455 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON ENDOSCOPIC OUTCOME MEASURES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
Geert D’Haens(Amsterdam University Medical Centers), Brian G. Feagan(Western University), Mary Ellen Frustaci(Johnson & Johnson (United States)), Zijiang Yang(Henan Medical University), Louis R. Ghanem(Johnson & Johnson (United States)), Daphne Chan(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Julián Panés(Hospital Clínic de Barcelona), David T. Rubin(University of California System), Melissa Cunningham(Medical University of South Carolina), Susana Gonzalez, Omoniyi J. Adedokun(Western University), Jewel Johanns(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 9
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k